99.19
1.02%
-0.92
Glaukos Corporation stock is currently priced at $99.19, with a 24-hour trading volume of 40,476.
It has seen a -1.02% decreased in the last 24 hours and a +10.46% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $99.18 pivot point. If it approaches the $101.2 resistance level, significant changes may occur.
Previous Close:
$100.11
Open:
$100.28
24h Volume:
40,476
Market Cap:
$5.02B
Revenue:
$314.71M
Net Income/Loss:
$-134.66M
P/E Ratio:
-36.87
EPS:
-2.69
Net Cash Flow:
$-78.01M
1W Performance:
+2.68%
1M Performance:
+10.46%
6M Performance:
+46.08%
1Y Performance:
+111.31%
Glaukos Corporation Stock (GKOS) Company Profile
Name
Glaukos Corporation
Sector
Industry
Phone
949-367-9600
Address
229 Avenida Fabricante, San Clemente, CA
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-21-23 | Upgrade | JP Morgan | Neutral → Overweight |
Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
Nov-28-23 | Initiated | Truist | Buy |
Nov-08-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Jun-07-23 | Upgrade | Piper Sandler | Neutral → Overweight |
Dec-22-22 | Initiated | Mizuho | Neutral |
Dec-19-22 | Upgrade | JP Morgan | Underweight → Neutral |
Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
Oct-14-22 | Resumed | Stephens | Overweight |
Oct-04-22 | Initiated | Needham | Buy |
Jul-12-22 | Upgrade | Stifel | Hold → Buy |
Feb-03-22 | Upgrade | William Blair | Mkt Perform → Outperform |
Jan-19-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
Jan-18-22 | Upgrade | BTIG Research | Neutral → Buy |
Nov-03-21 | Upgrade | Stephens | Equal-Weight → Overweight |
Jul-26-21 | Downgrade | Stephens | Overweight → Equal-Weight |
Jul-20-21 | Downgrade | Wells Fargo | Equal Weight → Underweight |
Jul-14-21 | Downgrade | Oppenheimer | Outperform → Perform |
Jul-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
Apr-08-21 | Upgrade | Oppenheimer | Perform → Outperform |
Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
Dec-16-20 | Upgrade | Citigroup | Sell → Neutral |
Dec-09-20 | Initiated | Oppenheimer | Perform |
Nov-17-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
Oct-08-20 | Downgrade | JP Morgan | Neutral → Underweight |
Jun-15-20 | Initiated | Jefferies | Hold |
Mar-05-20 | Initiated | Citigroup | Sell |
Feb-28-20 | Downgrade | JP Morgan | Overweight → Neutral |
Jan-06-20 | Upgrade | Berenberg | Hold → Buy |
Dec-12-19 | Downgrade | Wells Fargo | Outperform → Underperform |
Sep-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
Mar-08-19 | Initiated | BTIG Research | Neutral |
Aug-30-18 | Initiated | Berenberg | Hold |
Aug-29-18 | Upgrade | JP Morgan | Neutral → Overweight |
Aug-03-18 | Reiterated | Stifel | Hold |
Jun-21-18 | Downgrade | JP Morgan | Overweight → Neutral |
Apr-13-18 | Downgrade | Stifel | Buy → Hold |
Mar-01-18 | Reiterated | Cantor Fitzgerald | Buy |
Mar-02-17 | Reiterated | Cantor Fitzgerald | Overweight |
Jan-06-17 | Upgrade | Stifel | Hold → Buy |
Oct-27-16 | Initiated | Wells Fargo | Outperform |
View All
Glaukos Corporation Stock (GKOS) Latest News
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
Zacks Investment Research
Glaukos (GKOS) Gains Nearly 25% YTD: What's Driving the Rally?
Zacks Investment Research
Analyst Ratings For Glaukos
Benzinga
Glaukos (GKOS) Hits 52-Week High: What's Driving the Stock?
Zacks Investment Research
Glaukos' (GKOS) iDose TR Receives Permanent J- Code From CMS
Zacks Investment Research
Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday
Benzinga
Glaukos Corporation Stock (GKOS) Financials Data
Glaukos Corporation (GKOS) Revenue 2024
GKOS reported a revenue (TTM) of $314.71 million for the quarter ending December 31, 2023, a +11.26% rise year-over-year.
Glaukos Corporation (GKOS) Net Income 2024
GKOS net income (TTM) was -$134.66 million for the quarter ending December 31, 2023, a -35.75% decrease year-over-year.
Glaukos Corporation (GKOS) Cash Flow 2024
GKOS recorded a free cash flow (TTM) of -$78.01 million for the quarter ending December 31, 2023, a -23.14% decrease year-over-year.
Glaukos Corporation (GKOS) Earnings per Share 2024
GKOS earnings per share (TTM) was -$2.78 for the quarter ending December 31, 2023, a -33.01% decline year-over-year.
Glaukos Corporation Stock (GKOS) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Hoffmeister David F | Director |
Apr 10 '24 |
Option Exercise |
7.28 |
10,000 |
72,750 |
15,767 |
Gilliam Joseph E | PRESIDENT & COO |
Apr 08 '24 |
Option Exercise |
41.69 |
59,801 |
2,493,104 |
161,646 |
Gilliam Joseph E | PRESIDENT & COO |
Apr 08 '24 |
Sale |
100.47 |
59,801 |
6,008,359 |
101,845 |
Thurman Alex R. | SVP & CHIEF FINANCIAL OFFICER |
Apr 08 '24 |
Sale |
100.54 |
1,372 |
137,944 |
52,532 |
Gilliam Joseph E | PRESIDENT & COO |
Apr 05 '24 |
Option Exercise |
55.18 |
2,457 |
135,577 |
104,302 |
Gilliam Joseph E | PRESIDENT & COO |
Apr 05 '24 |
Sale |
96.81 |
2,457 |
237,862 |
101,845 |
Thurman Alex R. | SVP & CHIEF FINANCIAL OFFICER |
Apr 05 '24 |
Sale |
96.63 |
262 |
25,316 |
53,904 |
Gilliam Joseph E | PRESIDENT & COO |
Apr 04 '24 |
Option Exercise |
55.18 |
200 |
11,036 |
102,045 |
Thurman Alex R. | SVP & CHIEF FINANCIAL OFFICER |
Apr 04 '24 |
Sale |
95.33 |
434 |
41,371 |
54,166 |
Gilliam Joseph E | PRESIDENT & COO |
Apr 04 '24 |
Sale |
96.57 |
200 |
19,314 |
101,845 |
About Glaukos Corporation
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry; iStent Supra suprachoroidal micro-bypass stent, which is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. Its product pipeline also consists of iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure; and iStent Infinite trabecular micro-bypass system, which is used as a standalone procedure in patients with refractory glaucoma. The company markets its products through direct sales force in the United States and internationally, as well as through distribution partners in Europe, the Asia Pacific, Latin America, and internationally. Glaukos Corporation has a collaboration agreement with D. Western Therapeutics Institute for the development of novel intraocular products for the treatment of glaucoma. The company was founded in 1998 and is headquartered in San Clemente, California.
Cap:
|
Volume (24h):